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Graft-vs.-leukemia (GvL) activity is 
a crucial principle of allogeneic hemato-
poietic stem cell transplantation (allo-
HSCT) and underlies curative responses 
observed in many patients with advanced 
hematologic malignancies who undergo 
this treatment modality.1 As a therapeu-
tic strategy, allo-HSCT has the benefit of 
resulting in the engraftment of a normal 
donor immune system that has the poten-
tial to overcome host immune defects. 
In particular, donor-derived T cells are 
thought to be the primary cells respon-
sible for the effectiveness of allo-HSCT 
as they may recognize host antigens 
including tumor-associated or -specific 
antigens (i.e., neoantigens, overexpressed 
antigens, antigens selectively expressed 
in malignant cells or viral antigens) and 
alloantigens, which arise from differences 
in genetic polymorphisms between donor 
and recipient (Fig. 1).1 The recognition 
of alloantigens by donor T cells has been 
thought to be the basis of the close associa-
tion between GvL effects (i.e., the immune 
response against alloantigens expressed on 
hematopoietic cells) and graft-vs.-host dis-
ease (GvHD, i.e., the immune response 
against broadly expressed alloantigens) in 
allo-HSCT recipients.1
With the development of reduced inten-
sity conditioning (RIC) regimens, in which 
donor cell engraftment can be achieved 
with diminished morbidity and mortality 
as compared with conventional myleoabla-
tive regimens, the safety of the transplant 
procedure itself has improved, but the 
long-term control of leukemia remains 
a challenge.2,3 Thus, the development of 
strategies for inducing ever more robust 
GvL responses under conditions of mini-
mal toxicity to achieve improved outcomes 
upon allo-HSCT remains a high priority.
One established approach to enhanc-
ing GvL in patients with relapsed hema-
tologic malignancies is donor lymphocyte 
infusion (DLI). However, the clinical 
responses to DLI are not universal and 
the toxicities associated with this proce-
dure are consistent with broad alloantigen 
stimulation.1 Alternatively, an appealing 
approach to stimulate GvL is to focus 
post-engraftment T cells on the tumor. 
An informative setting to implement and 
study strategies for enhancing GvL is allo-
HSCT in patients with advanced chronic 
lymphocytic leukemia (CLL), for several 
reasons.
First, clinical remissions in transplanted 
CLL patients have been associated with the 
induction of GvHD or have been recorded 
upon the withdrawal of immunosuppres-
sive GvHD-prophylactic medications, 
demonstrating that CLL is susceptible to 
immunological destruction and support-
ing the critical role of GvL responses in 
the control of CLL.4 Second, many CLL 
patients experience a relatively indolent dis-
ease course, which supplies the time that is 
required for the stimulation of GvL effects. 
Finally, malignant cells can be readily 
obtained from the peripheral blood of CLL 
patients, providing a reliable autologous 
source of tumor. The immunization of 
transplant recipients with CLL-associated 
antigens may boost antitumor immunity 
upon allo-HSCT, as the presentation of 
tumor antigens by stimulated dendritic 
cells may enhance donor T cell expan-
sion and function and help focus immune 
responses toward leukemia cells.5
We recently tested this hypothesis in 
a Phase I clinical trial. In this setting, 18 
patients with advanced CLL received up 
to six vaccine doses consisting of irradi-
ated autologous leukemia cells combined 
with the adjuvant granulocyte macrophage 
colony-stimulating factor (GM-CSF) 
within the first 2–3 months following allo-
HSCT.6 Vaccines were well tolerated, and 
the incidence of GvHD was similar to that 
observed in historical controls. Of note, we 
observed a rise in circulating CLL-specific 
(rather than alloreactive) CD8+ T cells and 
promising clinical activity in the study 
participants.6
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whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation 
stand out as a promising approach to enhance graft-vs.-leukemia responses. herein, the implications of this finding for 
the development of strategies to improve the outcome of patients subjected to allogeneic stem cell transplantation are 
discussed.
e26587-2 OncoImmunology Volume 2 Issue 11
Three features unique to our vaccina-
tion protocol may have been critical for its 
effectiveness (Fig. 1):
Antigen Source
We used CLL cells themselves as the 
source of CD4+ and CD8+ T cell antigens, 
since they are a reliable source of personal 
tumor antigens, including neoantigens. 
In contrast to vaccination with recombi-
nant pre-defined antigens, our autologous 
whole tumor-cell vaccination approach 
has the advantage of harnessing the pro-
file of immunogenic tumor antigens that 
is unique in each CLL patient.
Adjuvant
Our approach involved the combina-
tion of irradiated autologous leukemia 
cells with the continuous local production 
of GM-CSF. A reliable and standardized 
source of the adjuvant was provided by 
the HLA-negative human cell line K562, 
which was engineered to produce large 
amounts of GM-CSF. The paracrine pro-
duction of GM-CSF at the vaccination 
site can stimulate antigen presentation.7 
However, paradoxically, GM-CSF can 
also serve a regulatory role in dampening 
T cell responses and mediating immune 
homeostasis.7 Interestingly, we obtained 
evidence in support of both pro- and 
anti-inflammatory effects of GM-CSF in 
vaccinated patients, implying that in the 
early post-transplant setting, this cytokine 
may play a beneficial role in balancing the 
stimulation of antitumor immunity with-
out exacerbating GvHD.6
Timing
Our vaccine was administered between 
days 30 and 100 after allo-HSCT, 
while patients were on stable doses of 
GvHD-prophylactic medication. Together 
with the results of preclinical studies, our 
findings suggest that the efficacy of vacci-
nation may be improved by administration 
during the early post-transplant period. 
We think this is the case because (1) donor 
T cells are undergoing rapid homeostatic 
expansion in a lymphopenic setting (gen-
erated by the transplant conditioning 
regimen) and (2) are not functionally 
compromised by the immunosuppressive 
effects of a high tumor burden or chemo-
therapy (Fig. 1).6,8,9 Our findings argue 
against a more conventional point of view, 
in which the early post-transplant period 
is regarded as a poor platform for immu-
notherapy due to incomplete immune 
reconstitution and the immunosuppres-
sive effects of GvHD prophylaxis.
Our pilot clinical study suggests that 
a multi-epitope vaccination strategy can 
tip the balance between leukemia-specific 
and alloantigen-reactive immunity in favor 
Figure  1. whole tumor-cell vaccination early after allogeneic stem cell transplantation. subcutaneously injected irradiated autologous cancer cells 
provide a source of tumor antigens at the vaccination site (1). Granulocyte macrophage colony-stimulating factor (GM-CsF) secreted by irradiated 
bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site (2). The allograft 
contains hematopoietic precursor cells and mature T cells, which might be tumor-reactive, alloreactive or non-alloreactive. early after allogeneic stem 
cell transplantation (allo-hsCT), homeostatic cytokines support T cell expansion in the lymphopenic host (3). autologous whole tumor cell-based vacci-
nation may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect. GvhD, graft-vs.-host 
disease; s.c., subcutaneous; i.d., intradermal
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of GvL effects in transplant recipients. 
However, randomized studies with larger 
patient cohorts are required to determine 
whether our promising results translate into 
a definitive clinical benefit for patients.6
We propose that our findings provide 
the foundations for the development of 
new strategies that can be implemented to 
advance long-term leukemia control fol-
lowing HSCT. In particular, formulations 
based on neoantigens (identified by DNA 
and RNA sequencing) represent highly 
attractive next-generation post-transplant 
anticancer vaccines as they have the 
potential to induce T cell responses with 
exquisite specificity for malignant cells.10
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